Literature DB >> 24022808

Tailored versus standard dose prophylaxis in children with hemophilia A.

Cristina Santoro1, Erminia Baldacci, Caterina Mercanti, Maria Gabriella Mazzucconi.   

Abstract

Prophylaxis is universally recognized as the treatment of choice in people with hemophilia, and tailored prophylaxis is the consistent modification of the standard weight-based dosing regimen. A large number of factors guide the choice of a specific tailored regimen, and different regimens are under evaluation. Tailored low-dose frequent regimens are likely to be cost-effective, but they are less accepted by patients. Escalating dose regimens seem to be quite effective in preventing bleedings and, consequently, arthropathy, although data on long-term outcomes are still not available. Pharmacokinetic-driven approaches have been also proposed. Sensitive and validated tools able to reliably measure the different outcomes are necessary in this setting. With regard to the evaluation of arthropathy, magnetic resonance imaging and ultrasound are promising imaging techniques in detecting early joint damage. Factor VIII trough levels can be considered a measure of the efficacy of FVIII infused, although other factors influence the bleeding pattern. Global assays of coagulation could provide more complete information on the hemostatic potential of a sample and predict bleeding phenotype. These techniques are also promising for the individualization of prophylaxis regimens, potentially resulting in less frequent dosing, more comfortable and less expensive approaches. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24022808     DOI: 10.1055/s-0033-1354419

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  3 in total

Review 1.  Clinical use of factor VIII and factor IX concentrates.

Authors:  Massimo Morfini; Antonio Coppola; Massimo Franchini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 2.  Current and evolving features in the clinical management of haemophilia.

Authors:  Antonio Coppola; Massimo Morfini; Ernesto Cimino; Antonella Tufano; Anna M Cerbone; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

3.  A Cohort Pilot Study on HIV-Associated Neuropsychological Impairments in Hemophilia Patients.

Authors:  Silvia Riva; Ilaria Cutica; Caspar Krampe; Laura F Reinecke; William Russell-Edu; Cristina Santoro; Angiola Rocino; Elena Santagostino; Vega Rusconi; Gabriella Pravettoni
Journal:  Front Hum Neurosci       Date:  2015-06-02       Impact factor: 3.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.